Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

York Clinical Research

Neither a doctor nor a teaching hospital

Research payments

$143,644

24 payments

Through program year 2025, York Clinical Research is reported as receiving $143,644 in research payments, across 24 payments.

By program year

5 rows
Year Kind Amount Payments
2025 Research $10,418 17
2022 Research $84,710 3
2021 Research $44,012 1
2020 Research $3,713 1
2019 Research $792 2

Breakdown

Who paid Research payments · program years 2019–2025
  1. Novartis Pharmaceuticals Corporation $132,434 5 payments
  2. Boehringer Ingelheim Pharma GmbH & Co.KG $6,677 1 payment
  3. Moderna TX, Inc. $2,144 4 payments
  4. Boehringer Ingelheim International GmbH $814 10 payments
  5. Amgen Inc. $792 2 payments
  6. Boehringer Ingelheim Pharmaceuticals, Inc. $783 2 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Randomized Double-Blind, Placebo-Controlled, Multicenter Trial Assessing the Impact of Lipoprotein (A) Lowering With Tqj230 on Major Cardiovascular Events in Patients With Established Cardiovascular Disease $47,724 2 payments
  2. Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (Victorion-2 Prevent) $43,822 1 payment
  3. A Randomized, Controlled, Multicenter, Open-Label Trial Comparing A Post-Discharge Care Pathway Involving Aggressive LDL-C Management With Inclisiran With Usual Care in Patients With A Recent Acute Coronary Syndrome $30,894 1 payment
  4. A Multi-Center, Randomized, Double-Blind, Parallel-Group, 20-Week Dose-Finding Study to Evaluate Efficacy, Safety, and Tolerability of Xxb750 in Patients With Resistant Hypertension $9,993 1 payment
  5. A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. $8,274 13 payments
  6. A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age $2,144 4 payments
  7. Gould $515 1 payment
  8. Galactic-Hf $277 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record